Introduction {#sec1_1}
============

Cardiovascular morbidity and mortality are extremely high in patients with chronic kidney disease (CKD) \[[@B1]\]. Whereas classical risk factors, such as high blood pressure and cholesterol, contribute to cardiovascular disease in the early stages of CKD, non-traditional risk factors, including disorders of mineral metabolism, play a prevailing role in the vascular abnormalities of patients with advanced CKD \[[@B2]\].

In CKD not only the aorta and large conduit arteries may be affected but also the microcirculation, consisting of small arteries and arterioles, capillaries and venules \[[@B3]\]. In long-standing CKD, blood vessels are characterized by extensive calcifications in both the intimal and medial layers, leading to an increased vascular stiffening and loss of compliance. As a result, both the pulsatile component of blood pressure, as indicated by an augmented pulse pressure, and peripheral resistance, expressed as mean arterial pressure, are increased \[[@B4]\]. In the microcirculation, these changes may lead to an attenuated vasodilatory capacity and loss of capillary architecture and rarefaction \[[@B5]\]. Indeed, in patients with advanced CKD, it has recently been shown that the functional and structural number of capillaries, as analyzed by capillary nailfold microscopy, is decreased \[[@B6]\]. Blunted post-ischemic increase in skin blood flowmotion by laser Doppler tracing can be considered an early sign of microvascular endothelial dysfunction in CKD \[[@B7]\].

In addition to CKD, aging is also associated with an attenuated vasodilator response of the microcirculation to a variety of stimuli \[[@B8], [@B9], [@B10], [@B11], [@B12]\] which is largely the result of endothelial dysfunction. Accelerated vascular aging, associated with Klotho deficiency, is a characteristic of subjects with CKD \[[@B13], [@B14], [@B15]\]. Even in childhood, end-stage renal disease (ESRD) is associated with structural abnormalities in arterial wall properties, comparable with adult levels \[[@B16]\]. Research on vascular calcification and stiffness in CKD patients was focused mainly on coronary and other large arteries, but little is known about microcirculatory dysfunction.

In this study, the effect of age on endothelium-dependent and endothelium-independent vasoreactivity in the microcirculation, as assessed non-invasively by iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP), respectively, was explored both in a group of healthy subjects and in a group of patients with advanced CKD.

Patients and Methods {#sec1_2}
====================

Patients and Controls {#sec2_1}
---------------------

A total of 52 patients \[16 patients with CKD stage 4--5 not yet on dialysis with an estimated glomerular filtration rate (eGFR) \<20 ml/min\], 20 hemodialysis (HD) and 16 peritoneal dialysis patients were recruited from the outpatient clinic and the dialysis unit of our hospital after giving informed consent. Thirty-three apparently healthy subjects served as controls. All study subjects were between 20 and 75 years old. Exclusion criteria were: life expectancy \<3 months due to non-renal disease, diabetes mellitus, as defined by medical treatment for diabetes or a fasting glucose \>6.0 mmol/l, and active auto-immune disease. The study protocol was approved by the local ethics committee.

Laboratory Values {#sec2_2}
-----------------

Kidney function, expressed as eGFR normalized for 1.73 m^2^ BSA, was calculated by the Cockcroft and Gault formula in controls and by the mean of urine creatinine and urea clearances in CKD patients. Parameters of mineral metabolism (calcium corrected for albumin, phosphorus, intact parathyroid hormone) and routine laboratory parameters (hemoglobin, albumin and bicarbonate) were measured in patients with CKD. All blood samples were drawn in the fasting state. Intact parathyroid hormone levels were measured by a commercially available immunometric assay (Luminescence Architect; Abbott Laboratories, Chicago, Ill., USA).

Clinical Characteristics {#sec2_3}
------------------------

Clinical history and medication use were assessed by information from medical charts. Body mass index (BMI) was calculated from weight and height measurements. Patients were considered to have a history of cardiovascular events if there was a previous stroke or cardiac event, including myocardial infarction, congestive heart failure and angina, or clinical peripheral vascular disease. The causes of renal disease are described in table [2](#T2){ref-type="table"}.

Iontophoresis {#sec2_4}
-------------

Endothelium-(in)dependent vasodilation of finger skin microcirculation was evaluated by iontophoresis in combination with laser Doppler flowmetry \[[@B17]\]. Laser Doppler flowmetry is a non-invasive method to measure skin perfusion. A laser beam penetrates the skin and a fraction of the light is backscattered by moving blood objects and undergoes a frequency shift according to the Doppler principle, generating a signal proportional to tissue perfusion. Laser Doppler flux was measured on the middle phalanx of the third and fourth finger on the non-dominant hand with the Periflux 4000 system (Perimed) and expressed as arbitrary perfusion units. In HD patients, measurements were obtained from the contralateral shunt arm. HD patients were treated twice or thrice weekly and analyzed on a midweek non-dialysis day. Iontophoresis is a non-invasive method of drug application that allows the local transfer of charged substances across the skin by use of a small electric current. A battery-powered iontophoresis controller (Phoresor II; Iomed) was used to provide a direct current for drug iontophoresis. ACh (1%, Miochol; IOLAB, Bournonville Pharma) was delivered with an anodal current on the middle finger: 7 doses (0.1 mA for 20 s) were delivered, with a 60-second interval between each dose. A 60-second interval between each iontophoresis period was required to achieve the plateau of the response following each delivery of ACh. Day-to-day variation coefficient of the relative increase from baseline to the final two deliveries was 9.8 ± 5.6% as determined in 9 subjects on two occasions. SNP (0.01%, Nipride; Roche) was delivered with a cathodal current; 9 doses (0.2 mA for 20 s) were delivered, with a 120-second interval between each dose. A 120-second interval between each iontophoresis period was required to achieve the plateau of the response after each delivery of SNP. Day-to-day variation coefficient of the relative increase from baseline to the final two deliveries was 8.3 ± 5.4% as determined in 9 subjects on two occasions. Because the responses to vehicle are known to be negligible compared with responses to ACh and SNP, we refrained from doing vehicle control studies.

ACh-mediated and SNP-mediated vasodilations were defined as percentage increase from baseline to the final 2 min of the plateau phase. Additional analyses were performed by measuring the absolute increase in perfusion units and by measuring the area under the response curve for ACh and SNP.

Statistical Analysis {#sec2_5}
--------------------

Variables are presented as mean ± SD or as median, 10th--90th percentile and interquartile range. When appropriate, data with a skewed distribution were log-transformed. ANOVA was used to compare differences between healthy controls and CKD patients. Non-parametric tests were used in the case of small numbers or abnormally distributed data sets. Linear regression analysis was applied to explore various demographic and clinical determinants of ACh- or SNP-mediated vasodilation. A p value of \<0.05 was considered statistically significant. All analyses were performed with the statistical software package SPSS version 18.0 (SPSS Inc., Chicago, Ill., USA).

Results {#sec1_3}
=======

Demographic, Clinical and Laboratory Characteristics {#sec2_6}
----------------------------------------------------

Baseline characteristics of patients and controls are shown in table [1](#T1){ref-type="table"}. Control subjects were all non-smokers and did not use any medication. Median eGFR in healthy controls was 90 ml/min/1.73 m^2^, in CKD stage 4--5 patients 11 ml/min/1.73 m^2^ and in ESRD patients 4 ml/min/1.73 m^2^. Dialysis vintage of peritoneal dialysis patients was not significantly different from HD patients (1.76 ± 1.06 and 2.20 ± 2.51 years, respectively). ACh-mediated and SNP-mediated vasodilations were similar in these groups. Systolic blood pressure was significantly higher in CKD stage 4--5 patients than in healthy controls. The mean ages in healthy controls, CKD stage 4--5 and ESRD patients were 49.5 ± 16.7, 56.9 ± 11.5 and 55.0 ± 13.9 years, respectively (table [1](#T1){ref-type="table"}). As age is an important determinant of microvascular function \[[@B18]\], and it was different between control subjects and advanced CKD patients, a subdivision was made according to age. The primary goal was to create subgroups with identical 'old age' amongst healthy controls and patients with advanced CKD. For this purpose, the division between 'old' and 'young' was arbitrarily set at 45 years. The mean ages in the group of old healthy controls and old CKD patients were 60.9 ± 7.1 and 61.1 ± 7.8 years, respectively (table [2](#T2){ref-type="table"}). In both 'young' groups, age was a bit less well matched (controls 29.5 ± 5.4 years, CKD patients 34.9 ± 7.2 years). Laboratory values of the patients, including markers of mineral metabolism, are shown in table [2](#T2){ref-type="table"}.

Microvascular Function {#sec2_7}
----------------------

### Comparison between Healthy Controls and Patients with Advanced CKD {#sec3_1}

Both ACh- and SNP-mediated vasodilations were similar in CKD stage 4--5 and ESRD patients \[median (interquartile range) Ach-mediated vasodilations 287 (113--1,226) and 313 (158--781), respectively, p = 0.79; SNP-mediated vasodilations 396 (191--730) and 333 (125--744), respectively, p = 0.75\]. Therefore, these groups were pooled and denoted 'advanced CKD'. From our analysis it appeared, first, that ACh-mediated and SNP-mediated vasodilations in young patients with advanced CKD were impaired, if compared with young healthy controls. Second, microvascular function in young patients with advanced CKD is similar to both old healthy controls and elderly patients with advanced CKD (fig. [1](#F1){ref-type="fig"}). Similar results were obtained by measuring the percentage increase from baseline to the final 2 min of the plateau phase, the absolute increase in perfusion units, or by measuring the area under the response curve for both ACh and SNP (data not shown).

### Correlations between Microvascular Function, and Demographic and Clinical Variables in Healthy Controls {#sec3_2}

In healthy controls, linear regression analysis demonstrated that age and systolic blood pressure were inversely correlated with log ACh-mediated vasodilation, while eGFR showed a positive correlation (table [3](#T3){ref-type="table"}). With respect to log SNP-mediated vasodilation, age and systolic blood pressure were inversely and female gender positively associated.

### Correlations between Microvascular Function, and Demographic and Clinical Variables in Patients with CKD {#sec3_3}

In patients with advanced CKD, linear regression analysis showed that age and diastolic blood pressure were positively correlated with log ACh-mediated vasodilation (table [4](#T4){ref-type="table"}). There were no correlations between calcium and phosphate levels, and Ach-mediated or SNP-mediated vasodilation.

Discussion {#sec1_4}
==========

Increasing age and advanced CKD are both associated with an attenuated vasodilator response of the skin microcirculation \[[@B8], [@B9], [@B10], [@B11], [@B12]\]. However, whether aging impairs endothelium-dependent vasoreactivity in CKD patients even further is presently unknown. Our study demonstrates that microvascular function, as assessed with laser Doppler in combination with the iontophoretic delivery of ACh and SNP onto the skin, was inversely associated with age in healthy individuals, but not in patients with advanced CKD. Young patients with advanced CKD showed impaired vasodilation compared to young healthy controls. No differences could be observed between young patients with advanced CKD and both old healthy controls and elderly patients with CKD. Together, these data are compatible with the concept of premature aging of the vasculature in patients with CKD \[[@B16], [@B19]\].

In previous reports, microvascular dysfunction has been extensively described, not only in patients with diabetes mellitus \[[@B20], [@B21]\], hypertension \[[@B22]\] and coronary heart disease \[[@B23]\], but also in patients with CKD \[[@B24], [@B25]\]. In patients with advanced CKD, we recently demonstrated substantial capillary rarefaction both at baseline, after hyperemic stimulation and after venous occlusion \[[@B6]\]. Together these alterations suggested not only a functional, but also a structural disorder of the microcirculation in the skin of these patients. Klotho deficiency is associated with hyperphosphatemia-induced accelerated aging. Decreased Klotho expression is supposed to be the initiator of CKD-MBD pathophysiology \[[@B13], [@B14], [@B15]\]. As cutaneous capillary rarefaction was strongly and inversely correlated with serum phosphate levels \[[@B6]\], and high phosphate levels in CKD patients are associated with calcifications in the media of large and medium-size blood vessels \[[@B26], [@B27]\], calcified depositions in the subendothelial layers of the microcirculation may contribute to these findings \[[@B6], [@B28]\]. In the present analysis, we speculated that these pathophysiological changes would lead to deficient endothelium-dependent and endothelium-independent responses to locally administered vasodilatory stimuli.

In patients with CKD, both a blunted and a normal response to ACh and SNP have been described. However, in publications showing a reduced response, the control group was either younger, hypertensive or incompletely described \[[@B24], [@B29], [@B30]\]. When normotensive CKD patients were compared with age-matched controls \[[@B31]\], no marked differences were found. Actually, aging per se appeared to be associated with reduced skin reactivity, as elderly persons showed a lower dose-response curve after both ACh \[[@B32]\] and insulin \[[@B33]\]. By contrast, in comparison with age-matched controls, both thermal \[[@B25], [@B34]\] and reactive hyperemia \[[@B25]\] in the volar forearm were considerably reduced in patients with CKD, and even more in the presence of cardiovascular disease and diabetes mellitus \[[@B25]\]. Whether differences in methodology -- thermal and reactive hyperemia versus the iontophoretic delivery of ACh and SNP -- or dissimilar demographic and/or clinical characteristics explain the contrasting findings in patients with advanced CKD is not readily apparent from these studies.

Our study confirms and extends previous findings that age influences the vasoreactivity of the microcirculation in both the kidney and the skin of healthy subjects \[[@B30], [@B35]\]. With respect to microvascular function, our study suggests that premature aging occurs in young patients with advanced CKD. As differences were not found between old healthy controls and elderly patients with advanced CKD, it appears that age itself is of paramount importance for the observed decrease in microvascular reactivity. The presence of uremia, as manifested by various laboratory abnormalities, including disorders of mineral metabolism, did not aggravate these alterations. Hence, it appears that in the elderly, the uremic state itself has no additional negative influence on microvascular reactivity in skin on top of the alterations induced by aging itself.

Remarkably, in patients with advanced CKD, linear regression analysis demonstrated that older age and higher diastolic blood pressure were slightly associated with preserved ACh-mediated vasodilation. In this respect, it is interesting to note that elderly adults with low diastolic blood pressure have a higher risk of death \[[@B36]\]. Apart from survival bias, the long-lasting use of vasoactive medication, such as ACE inhibitors or beta-blockers, may contribute to these findings. The design of our study, however, does not permit such a far-reaching conclusion.

Interestingly, in healthy insulin-sensitive overweight individuals, it was recently found that both endothelial-dependent and independent cutaneous vasodilations were undisturbed, despite marked capillary rarefaction in these patients \[[@B37]\]. Hence, capillary rarefaction may occur independently from microcirculatory dysfunction, not only in obese diabetic patients but also in patients with advanced CKD.

Our study has important limitations. First, as many patients with advanced CKD are treated with anti-hypertensive and phosphorus-binding medication, it is conceivable that these drugs influenced endothelium-dependent and endothelium-independent vasodilations. Second, whereas tobacco use was an exclusion criterion in the control group, patients who smoked were not excluded. Defining smoking as an exclusion criterion, in addition to diabetes and auto-immune diseases, would have precluded a substantial amount of patients from the study. Third, as the group of patients with advanced CKD consisted of individuals with CKD stage 4--5 and ESRD, our data must be interpreted with caution due to the heterogeneity of this group.

To summarize, whereas age was inversely associated with microvascular function in healthy individuals, no such correlation was found in patients with advanced CKD. In young patients with advanced CKD, endothelium-dependent and endothelium-independent vasodilations, as measured by the iontophoretic delivery of ACh and SNP onto the skin, were impaired if compared to young healthy controls. As microvascular reactivity in young patients with advanced CKD was similar to old healthy controls and old patients with CKD, premature aging may underlie these findings.

This study was supported by Baxter Healthcare Corporation.

![ACh- and SNP-mediated vasodilations, defined as percentage increase from baseline to the final 2 min of the plateau phase. A box represents the 25th--75th percentile range, the whiskers represent the 10th--90th percentile range and the line within the boxes the median value.](nne-0002-0283-g01){#F1}

###### 

Demographic variables

                                             Healthy controls   CKD stage 4--5   ESRD
  ------------------------------------------ ------------------ ---------------- -------------
  Number (male/female)                       33 (19/14)         16 (10/6)        36 (28/8)
  Mean age ± SD, years                       49.5 ± 16.7        56.9 ± 11.5      55.0 ± 13.9
  BMI                                        24.3 ± 2.7         25.9 ± 4.3       23.9 ± 3.4
  Systolic blood pressure, mm Hg             126 ± 17\*         148 ± 30\*       139 ± 25
  Diastolic blood pressure, mm Hg            79 ± 9             85 ± 16          80 ± 10
  eGFR, ml/min/1.73 m^2^                     90 \[76--108\]     11 \[8--13\]     4 \[0--6\]
  History of cardiovascular disease, n (%)   0                  4 (25)           9 (25)
  Dialysis vintage, years                                                        
    Peritoneal dialysis patients (n = 16)                                        1.76 ± 1.06
    Hemodialysis patients (n = 20)                                               2.20 ± 2.51
  Smoking, n (%)                             0                  8 (50)           18 (50)
  Medication                                                                     
    Diuretic use, n (%)                                         7 (44)           18 (50)
    Inhibitors of RAAS, n (%)                                   13 (81)          25 (69)
    Calcium antagonist, n (%)                                   10 (63)          12 (33)
    Beta-blocker, n (%)                                         8 (50)           23 (64)
    Calcium carbonate, n (%)                                    4 (25)           22 (61)
    Sevelamer, n (%)                                            5 (31)           25 (69)
    Lanthanum carbonate, n (%)                                  0                9 (25)

Data are presented as mean ± SD or as median \[interquartile range\]. RAAS = Renin angiotensin aldosterone system. \* p \< 0.01 healthy controls vs. CKD stage 4--5.

###### 

Demographic variables: groups were split into subgroups consisting of persons over and under 45 years

                                               Young healthy controls   Young advanced CKD   Old healthy controls   Old advanced CKD   
  -------------------------------------------- ------------------------ -------------------- ---------------------- ------------------ -------------
  Number (male/female)                         12 (7/5)                 11 (8/3)             21 (12/9)              41 (30/11)         
  Mean age ± SD, years                         29.5 ± 5.4               34.9 ± 7.2           60.9 ± 7.1             61.1 ± 7.8         
  BMI                                          23.7 ± 2.3               22.8 ± 4.7           24.7 ± 3.0             25.0 ± 3.4         
  Systolic blood pressure, mm Hg               113 ± 13^\#^             128 ± 20             134 ± 15^\#^           145 ± 27^\#^       
  Diastolic blood pressure, mm Hg              73 ± 8^\#^               77 ± 10              83 ± 7^\#^             83 ± 13^\#^        
  eGFR, ml/min                                 116 \[96--121\]          5 \[0--7\]           85 \[7--98\]           6 \[3--12\]        
  Cause of renal disease                                                                                                               
    Hypertension, n (%)                                                 5 (46)                                      23 (56)            
    Hereditary disease, n (%)                                           3 (27)                                      10 (24)            
    Immune-complex glomerulonephritis, n (%)                            0                                           5 (12)             
    Others, n (%)                                                       3 (27)                                      3 (7)              
  History of cardiovascular disease, n (%)     0                        0                    0                      13 (32)            
  Smoking, n (%)                               0                        4 (36)               0                      22 (54)            
  Laboratory values                                                                                                                    
    Calcium, mmol/l                            {2.2--2.6}                                    2.31 ± 0.21                               2.39 ± 0.14
    Phosphorus, mmol/l                         {0.7--1.4}                                    1.74 ± 0.44                               1.62 ± 0.39
    Albumin, g/l                               {35--52}                                      38 ± 3.5                                  37.5 ± 3.7
    Parathyroid hormone, pmol/l                {0--11}                                       17 (1--69)                                26 (17--37)
    Bicarbonate, mmol/l                        {22.0--26.0}                                  24.1 ± 4.7                                22.6 ± 3.0
    Hemoglobin, mmol/l                         {7.5--11}                                     7.5 ± 0.9                                 7.4 ± 0.9

Data are presented as mean ± SD or as median \[interquartile range\]. Reference values are in braces. \# p \< 0.05 young healthy controls vs. old healthy controls/old advanced CKD patients.

###### 

Correlations between demographic and clinical parameters with microvascular function (log ACh-mediated and log SNP-mediated vasodilation) by linear regression analysis in healthy controls (n = 33)

  Determinant                       B       95% CI            p           r
  --------------------------------- ------- ----------------- ----------- -------
  *log ACh-mediated vasodilation*                                         
  Age, years                        −0.01   −0.02 to −0.002   **0.02**    −0.41
  Female gender                     −0.09   −0.41 to 0.24     0.58        −0.10
  eGFR, ml/min                      0.01    0.002 to 0.02     **0.02**    0.44
  BMI                               −0.03   −0.09 to 0.03     0.31        −0.18
  Systolic blood pressure, mm Hg    −0.01   −0.02 to −0.001   **0.02**    −0.39
  Diastolic blood pressure, mm Hg   −0.01   −0.03 to 0.01     0.30        −0.19
                                                                          
  *log SNP-mediated vasodilation*                                         
  Age, years                        −0.01   −0.02 to −0.001   **0.03**    −0.38
  Female gender                     0.31    0.05 to 0.57      **0.02**    0.40
  eGFR, ml/min                      0.01    −0.002 to 0.01    0.13        0.29
  BMI                               −0.02   −0.07 to 0.03     0.38        −0.16
  Systolic blood pressure, mm Hg    −0.01   −0.02 to −0.004   **0.003**   −0.50
  Diastolic blood pressure, mm Hg   −0.02   −0.03 to −0.002   0.03        −0.39

###### 

Associations between demographic and clinical parameters with microvascular function (log ACh-mediated and log SNP-mediated vasodilation) by linear regression analysis in patients with advanced CKD (n = 52)

  Determinant                       B        95% CI         p           r
  --------------------------------- -------- -------------- ----------- -------
  *log ACh-mediated vasodilation*                                       
  Age, years                        0.02     0.00--0.03     **0.05**    0.28
  Female gender                     0.15     −0.29--0.59    0.49        0.10
  eGFR, ml/min                      0.01     −0.03--0.05    0.57        0.08
  BMI                               −0.04    −0.09--0.01    0.09        −0.24
  Systolic blood pressure, mm Hg    0.01     −0.001--0.01   0.12        0.22
  Diastolic blood pressure, mm Hg   0.02     0.01--0.04     **0.003**   0.41
  Phosphate, mmol/l                 −0.26    −0.75--0.23    0.30        −0.15
  Calcium, mmol/l                   0.65     −0.56--1.87    0.28        0.15
                                                                        
  *log SNP-mediated vasodilation*                                       
  Age, years                        −0.002   −0.01--0.01    0.74        −0.05
  Female gender                     0.04     −0.25--0.33    0.80        0.04
  eGFR, ml/min                      0.01     −0.02--0.04    0.53        0.09
  BMI                               −0.03    −0.06--0.01    0.10        −0.23
  Systolic blood pressure, mm Hg    0.00     −0.01--0.004   0.84        −0.03
  Diastolic blood pressure, mm Hg   0.003    −0.01--0.01    0.61        0.07
  Phosphate, mmol/l                 −0.01    −0.34--0.31    0.95        −0.01
  Calcium, mmol/l                   −0.48    −1.27--0.31    0.23        −0.17
